Anti-Human DR5 (Drozitumab) – Fc Muted™ HRP

Pricing & Details

Product No.LT707
Clone
PRO95780
Protein
DR5
Formats AvailableView All
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
DR5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5
Applications
ELISA
,
FA
,
FC
Prod No.
Size
Price
Avail.
Qty
Add to cart
LT707-100 μg
100 µg
$405.00
Made to Order
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Human
Expression Host
HEK-293
FC Effector Activity
Muted
Immunogen
DR5 scFv
Product Concentration
0.5 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Formulation
This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
Storage and Handling
This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Drozitumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
ELISA
Other Applications Reported In Literature ?
FA
Additional Reported Applications For Relevant Conjugates ?
Agonist
WB
IP
IF
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Drozitumab. Clone PRO95780 recognizes human death receptor 5 (DR5). This product is for research use only.
Antigen Distribution
DR5 is widely expressed in adult and fetal tissues, with notably high expression on tumor cells.
Background
Drozitumab is a monoclonal antibody that specifically binds to human DR5. DR5 is expressed in a variety of solid tumors and hematologic malignancies, which are characteristically resistant to apoptosis. Drozitumab is a proapoptotic receptor agonists (PARA) that induces apoptosis in a variety of human cancer cell lines and xenograft models, both alone and in tandem with other antineoplastic agents.1 Apoptosis of cancer cells triggered by the activation of DR5, occurs without affecting most normal cell types. Anti-Human DR5 (Drozitumab) utilizes the same variable regions from the therapeutic antibody Drozitumab making it ideal for research projects.

Antigen Details

Protein
PubMed
NCBI Gene Bank ID
Research Area
Apoptosis
.
Cell Death
.
Immunology
.
Tumor Suppressors

References & Citations

1. Mendelson, D. et al. (2010) Clin Cancer Res. 16(4):1256-63.
Elisa Sandwich Protocol
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.